NCT02856919View on ClinicalTrials.gov

A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 13, 2016

Primary Completion Date

February 8, 2017

Study Completion Date

February 8, 2017

Conditions
Chronic Persistent Vascular Facial Erythema
Interventions
DRUG

brimonidine tartrate

Mirvaso® gel (5 mg/g brimonidine tartrate)

Trial Locations (5)

22471003

Instituto de Dermatologia e Estética do Brasil Ltda, Rio de Janeiro

91781200

Centro Brasileiro de Estudos em Dermatologia, Porto Alegre - RS

18603-440

Clinica Drmatologica Dra. Laura Buratini Ltda., Botucatu

04564000

Hosptial do Servidor Publico Municipal, São Paulo

09041-410

Fundação do ABC, São Paulo

All Listed Sponsors
collaborator

Eurotrials Brasil Consultores Cientificos Ltda

INDUSTRY

lead

Galderma Brasil Ltda.

INDUSTRY

NCT02856919 - A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema. | Biotech Hunter | Biotech Hunter